Home › Business › Business
Amgen lobbying in first quarter cost $2.5 million
STORY TOOLS 
More from BusinessWASHINGTON (AP) — Biotech drugmaker Amgen Inc. spent $2.5 million lobbying the federal government in the first quarter of 2008.
Amgen lobbied on legislation that would allow the Food and Drug Administration to approve generic copies of biotech drugs.
Generic drug companies already market cheaper versions of regular, chemical drugs, but the FDA does not have the authority to approve copies of biotech drugs, which are more complicated.
The biotech industry resisted efforts to create a generic biotech industry for nearly a decade. But with Democrats poised to pick up more seats in Congress this November, they are now pushing for a compromise before the political tide in Washington turns further in favor of their generic rivals.
Last year biotech makers opposed a bill that would have allowed pharmacists to switch patients to cheaper medications without their doctors' approval. The industry argued that only a doctor should be able to switch a patient's prescription to a generic. That distinction could let branded drug companies hold on to more sales.
They also want biotech medicines to be guaranteed at least 12 years on the market before having to compete with generic copies. Makers of generic drugs say any protection beyond five years is unreasonable. Senate lawmakers attempted to pass a compromise bill last year, but negotiations broke down over the length of exclusivity.
Amgen also lobbied on the implementation of the Medicare drug benefit for seniors and efforts to reform the U.S. patent system.
The Thousand Oaks-based company disclosed its lobbying expenditures in a form filed April 21 with the Senate's Office of Public Records.
(Requires free registration.)
Article discussions on this site are to support community debates of issues related to our stories and editorials.
Discussions should not stray from the subject of the story or editorial.
We do not allow the following:
We reserve the right to delete threads and/or ban users for these or other reasons we deem necessary.
Opinions are the sole responsibility of the person posting them. You agree not to post comments that are off topic, defamatory, obscene, abusive, threatening or an invasion of privacy. Violators may be banned. Click here for our full user agreement.